Medical University of Sofia

Allergic rhinitis is a symptomatic disorder of the nose\ninduced after allergen exposure by an IgE-mediated\ninflammation of the membranes lining the nose. It is a\nglobal health problem that causes major illness and disability\nworldwide. Over 600 million patients from all\ncountries, all ethnic groups and of all ages suffer from\nallergic rhinitis. It affects social life, sleep, school and\nwork and its economic impact is substantial.\nRisk factors for allergic rhinitis are well identified.\nIndoor and outdoor allergens as well as occupational\nagents cause rhinitis and other allergic diseases.\nThe role of indoor and outdoor pollution is probably\nvery important, but has yet to be fully understood\nboth for the occurrence of the disease and its manifestations.\nIn 1999, during the Allergic Rhinitis and its Impact on\nAsthma (ARIA) WHO workshop, the expert panel\nproposed a new classification for allergic rhinitis which\nwas subdivided into _intermittent_ or _persistent_ disease.\nThis classification is now validated.\nThe diagnosis of allergic rhinitis is often quite easy, but\nin some cases it may cause problems and many patients\nare still under-diagnosed, often because they do not\nperceive the symptoms of rhinitis as a disease impairing\ntheir social life, school and work.\nThe management of allergic rhinitis is well established\nand the ARIA expert panel based its recommendations\non evidence using an extensive review of the literature\navailable up to December 1999. The statements of\nevidence for the development of these guidelines followed\nWHO rules and were based on those of Shekelle et al.\nA large number of papers have been published since 2000\nand are extensively reviewed in the 2008 Update using\nthe same evidence-based system. Recommendations for\nthe management of allergic rhinitis are similar in both the\nARIA workshop report and the 2008 Update. In the\nfuture, the GRADE approach will be used, but is not yet\navailable.\nAnother important aspect of the ARIA guidelines was\nto consider co-morbidities. Both allergic rhinitis and\nasthma are systemic inflammatory conditions and often\nco-exist in the same patients. In the 2008 Update, these\nlinks have been confirmed.\nTheARIAdocument is not intended to be a standard-ofcare\ndocument for individual countries. It is provided as a\nbasis for physicians, health care professionals and\norganizations involved in the treatment of allergic rhinitis\nand asthma in various countries to facilitate the\ndevelopment of relevant local standard-of-care documents\nfor patients.

BACKGROUND: Vaccine development in the post-genomic era often begins with the in silico screening of genome information, with the most probable protective antigens being predicted rather than requiring causative microorganisms to be grown. Despite the obvious advantages of this approach--such as speed and cost efficiency--its success remains dependent on the accuracy of antigen prediction. Most approaches use sequence alignment to identify antigens. This is problematic for several reasons. Some proteins lack obvious sequence similarity, although they may share similar structures and biological properties. The antigenicity of a sequence may be encoded in a subtle and recondite manner not amendable to direct identification by sequence alignment. The discovery of truly novel antigens will be frustrated by their lack of similarity to antigens of known provenance. To overcome the limitations of alignment-dependent methods, we propose a new alignment-free approach for antigen prediction, which is based on auto cross covariance (ACC) transformation of protein sequences into uniform vectors of principal amino acid properties. RESULTS: Bacterial, viral and tumour protein datasets were used to derive models for prediction of whole protein antigenicity. Every set consisted of 100 known antigens and 100 non-antigens. The derived models were tested by internal leave-one-out cross-validation and external validation using test sets. An additional five training sets for each class of antigens were used to test the stability of the discrimination between antigens and non-antigens. The models performed well in both validations showing prediction accuracy of 70% to 89%. The models were implemented in a server, which we call VaxiJen. CONCLUSION: VaxiJen is the first server for alignment-independent prediction of protective antigens. It was developed to allow antigen classification solely based on the physicochemical properties of proteins without recourse to sequence alignment. The server can be used on its own or in combination with alignment-based prediction methods. It is freely-available online at the URL: http://www.jenner.ac.uk/VaxiJen.

Schizophrenia has a heritability of 60–80%1, much of which is attributable to common risk alleles. Here, in a two-stage genome-wide association study of up to 76,755 individuals with schizophrenia and 243,649 control individuals, we report common variant associations at 287 distinct genomic loci. Associations were concentrated in genes that are expressed in excitatory and inhibitory neurons of the central nervous system, but not in other tissues or cell types. Using fine-mapping and functional genomic data, we identify 120 genes (106 protein-coding) that are likely to underpin associations at some of these loci, including 16 genes with credible causal non-synonymous or untranslated region variation. We also implicate fundamental processes related to neuronal function, including synaptic organization, differentiation and transmission. Fine-mapped candidates were enriched for genes associated with rare disruptive coding variants in people with schizophrenia, including the glutamate receptor subunit GRIN2A and transcription factor SP4, and were also enriched for genes implicated by such variants in neurodevelopmental disorders. We identify biological processes relevant to schizophrenia pathophysiology; show convergence of common and rare variant associations in schizophrenia and neurodevelopmental disorders; and provide a resource of prioritized genes and variants to advance mechanistic studies. A genome-wide association study including over 76,000 individuals with schizophrenia and over 243,000 control individuals identifies common variant associations at 287 genomic loci, and further fine-mapping analyses highlight the importance of genes involved in synaptic processes.

BACKGROUND: Health literacy concerns the capacities of people to meet the complex demands of health in modern society. In spite of the growing attention for the concept among European health policymakers, researchers and practitioners, information about the status of health literacy in Europe remains scarce. This article presents selected findings from the first European comparative survey on health literacy in populations. M ETHODS: The European health literacy survey (HLS-EU) was conducted in eight countries: Austria, Bulgaria, Germany, Greece, Ireland, the Netherlands, Poland and Spain (n = 1000 per country, n = 8000 total sample). Data collection was based on Eurobarometer standards and the implementation of the HLS-EU-Q (questionnaire) in computer-assisted or paper-assisted personal interviews. R ESULTS: The HLS-EU-Q constructed four levels of health literacy: insufficient, problematic, sufficient and excellent. At least 1 in 10 (12%) respondents showed insufficient health literacy and almost 1 in 2 (47%) had limited (insufficient or problematic) health literacy. However, the distribution of levels differed substantially across countries (29-62%). Subgroups within the population, defined by financial deprivation, low social status, low education or old age, had higher proportions of people with limited health literacy, suggesting the presence of a social gradient which was also confirmed by raw bivariate correlations and a multivariate linear regression model. DISCUSSION: Limited health literacy represents an important challenge for health policies and practices across Europe, but to a different degree for different countries. The social gradient in health literacy must be taken into account when developing public health strategies to improve health equity in Europe.

Characterization of the genetic landscape of Alzheimer's disease (AD) and related dementias (ADD) provides a unique opportunity for a better understanding of the associated pathophysiological processes. We performed a two-stage genome-wide association study totaling 111,326 clinically diagnosed/'proxy' AD cases and 677,663 controls. We found 75 risk loci, of which 42 were new at the time of analysis. Pathway enrichment analyses confirmed the involvement of amyloid/tau pathways and highlighted microglia implication. Gene prioritization in the new loci identified 31 genes that were suggestive of new genetically associated processes, including the tumor necrosis factor alpha pathway through the linear ubiquitin chain assembly complex. We also built a new genetic risk score associated with the risk of future AD/dementia or progression from mild cognitive impairment to AD/dementia. The improvement in prediction led to a 1.6- to 1.9-fold increase in AD risk from the lowest to the highest decile, in addition to effects of age and the APOE ε4 allele.

OBJECTIVE: To analyze the clinical and immunologic manifestations of antiphospholipid syndrome (APS) in a large cohort of patients and to define patterns of disease expression. METHODS: The clinical and serologic features of APS (Sapporo preliminary criteria) in 1,000 patients from 13 European countries were analyzed using a computerized database. RESULTS: The cohort consisted of 820 female patients (82.0%) and 180 male patients (18.0%) with a mean +/- SD age of 42 +/- 14 years at study entry. "Primary" APS was present in 53.1% of the patients; APS was associated with systemic lupus erythematosus (SLE) in 36.2%, with lupus-like syndrome in 5.0%, and with other diseases in 5.9%. A variety of thrombotic manifestations affecting the majority of organs were recorded. A catastrophic APS occurred in 0.8% of the patients. Patients with APS associated with SLE had more episodes of arthritis and livedo reticularis, and more frequently exhibited thrombocytopenia and leukopenia. Female patients had a higher frequency of arthritis, livedo reticularis, and migraine. Male patients had a higher frequency of myocardial infarction, epilepsy, and arterial thrombosis in the lower legs and feet. In 28 patients (2.8%), disease onset occurred before age 15; these patients had more episodes of chorea and jugular vein thrombosis than the remaining patients. In 127 patients (12.7%), disease onset occurred after age 50; most of these patients were men. These patients had a higher frequency of stroke and angina pectoris, but a lower frequency of livedo reticularis, than the remaining patients. CONCLUSION: APS may affect any organ of the body and display a broad spectrum of manifestations. An association with SLE, the patient's sex, and the patient's age at disease onset can modify the disease expression and define specific subsets of APS.

IMPORTANCE: The Global Burden of Diseases, Injuries, and Risk Factors Study 2019 (GBD 2019) provided systematic estimates of incidence, morbidity, and mortality to inform local and international efforts toward reducing cancer burden. OBJECTIVE: To estimate cancer burden and trends globally for 204 countries and territories and by Sociodemographic Index (SDI) quintiles from 2010 to 2019. EVIDENCE REVIEW: The GBD 2019 estimation methods were used to describe cancer incidence, mortality, years lived with disability, years of life lost, and disability-adjusted life years (DALYs) in 2019 and over the past decade. Estimates are also provided by quintiles of the SDI, a composite measure of educational attainment, income per capita, and total fertility rate for those younger than 25 years. Estimates include 95% uncertainty intervals (UIs). FINDINGS: In 2019, there were an estimated 23.6 million (95% UI, 22.2-24.9 million) new cancer cases (17.2 million when excluding nonmelanoma skin cancer) and 10.0 million (95% UI, 9.36-10.6 million) cancer deaths globally, with an estimated 250 million (235-264 million) DALYs due to cancer. Since 2010, these represented a 26.3% (95% UI, 20.3%-32.3%) increase in new cases, a 20.9% (95% UI, 14.2%-27.6%) increase in deaths, and a 16.0% (95% UI, 9.3%-22.8%) increase in DALYs. Among 22 groups of diseases and injuries in the GBD 2019 study, cancer was second only to cardiovascular diseases for the number of deaths, years of life lost, and DALYs globally in 2019. Cancer burden differed across SDI quintiles. The proportion of years lived with disability that contributed to DALYs increased with SDI, ranging from 1.4% (1.1%-1.8%) in the low SDI quintile to 5.7% (4.2%-7.1%) in the high SDI quintile. While the high SDI quintile had the highest number of new cases in 2019, the middle SDI quintile had the highest number of cancer deaths and DALYs. From 2010 to 2019, the largest percentage increase in the numbers of cases and deaths occurred in the low and low-middle SDI quintiles. CONCLUSIONS AND RELEVANCE: The results of this systematic analysis suggest that the global burden of cancer is substantial and growing, with burden differing by SDI. These results provide comprehensive and comparable estimates that can potentially inform efforts toward equitable cancer control around the world.

Disorders of the brain can exhibit considerable epidemiological comorbidity and often share symptoms, provoking debate about their etiologic overlap. We quantified the genetic sharing of 25 brain disorders from genome-wide association studies of 265,218 patients and 784,643 control participants and assessed their relationship to 17 phenotypes from 1,191,588 individuals. Psychiatric disorders share common variant risk, whereas neurological disorders appear more distinct from one another and from the psychiatric disorders. We also identified significant sharing between disorders and a number of brain phenotypes, including cognitive measures. Further, we conducted simulations to explore how statistical power, diagnostic misclassification, and phenotypic heterogeneity affect genetic correlations. These results highlight the importance of common genetic variation as a risk factor for brain disorders and the value of heritability-based methods in understanding their etiology.

The American Diabetes Association and the European Association for the Study of Diabetes convened a panel to update the previous consensus statements on the management of hyperglycemia in type 2 diabetes in adults, published since 2006 and last updated in 2019. The target audience is the full spectrum of the professional health care team providing diabetes care in the U.S. and Europe. A systematic examination of publications since 2018 informed new recommendations. These include additional focus on social determinants of health, the health care system, and physical activity behaviors, including sleep. There is a greater emphasis on weight management as part of the holistic approach to diabetes management. The results of cardiovascular and kidney outcomes trials involving sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists, including assessment of subgroups, inform broader recommendations for cardiorenal protection in people with diabetes at high risk of cardiorenal disease. After a summary listing of consensus recommendations, practical tips for implementation are provided.

Here we report the Simons Genome Diversity Project data set: high quality genomes from 300 individuals from 142 diverse populations. These genomes include at least 5.8 million base pairs that are not present in the human reference genome. Our analysis reveals key features of the landscape of human genome variation, including that the rate of accumulation of mutations has accelerated by about 5% in non-Africans compared to Africans since divergence. We show that the ancestors of some pairs of present-day human populations were substantially separated by 100,000 years ago, well before the archaeologically attested onset of behavioural modernity. We also demonstrate that indigenous Australians, New Guineans and Andamanese do not derive substantial ancestry from an early dispersal of modern humans; instead, their modern human ancestry is consistent with coming from the same source as that of other non-Africans. Deep whole-genome sequencing of 300 individuals from 142 diverse populations provides insights into key population genetic parameters, shows that all modern human ancestry outside of Africa including in Australasians is consistent with descending from a single founding population, and suggests a higher rate of accumulation of mutations in non-Africans compared to Africans since divergence. Three international collaborations reporting in this issue of Nature describe 787 high-quality genomes from individuals from geographically diverse populations. David Reich and colleagues analysed whole-genome sequences of 300 individuals from 142 populations. Their findings include an accelerated estimated rate of accumulation of mutations in non-Africans compared to Africans since divergence, and that indigenous Australians, New Guineans and Andamanese do not derive substantial ancestry from an early dispersal of modern humans but from the same source as that of other non-Africans. Eske Willerlsev and colleagues obtained whole-genome data for 83 Aboriginal Australians and 25 Papuans from the New Guinea Highlands. They estimate that Aboriginal Australians and Papuans diverged from Eurasian populations 51,000–72,000 years ago, following a single out-of-Africa dispersal. Luca Pagani et al. report on a dataset of 483 high-coverage human genomes from 148 populations worldwide, including 379 new genomes from 125 populations. Their analyses support the model by which all non-African populations derive most of their genetic ancestry from a single recent migration out of Africa, although a Papuan contribution suggests a trace of an earlier human expansion.

The allergenic content of the atmosphere varies according to climate, geography and vegetation. Data on the presence and prevalence of allergenic airborne pollens, obtained from both aerobiological studies and allergological investigations, make it possible to design pollen calendars with the approximate flowering period of the plants in the sampling area. In this way, even though pollen production and dispersal from year to year depend on the patterns of preseason weather and on the conditions prevailing at the time of anthesis, it is usually possible to forecast the chances of encountering high atmospheric allergenic pollen concentrations in different areas. Aerobiological and allergological studies show that the pollen map of Europe is changing also as a result of cultural factors (for example, importation of plants such as birch and cypress for urban parklands), greater international travel (e.g. colonization by ragweed in France, northern Italy, Austria, Hungary etc.) and climate change. In this regard, the higher frequency of weather extremes, like thunderstorms, and increasing episodes of long range transport of allergenic pollen represent new challenges for researchers. Furthermore, in the last few years, experimental data on pollen and subpollen-particles structure, the pathogenetic role of pollen and the interaction between pollen and air pollutants, gave new insights into the mechanisms of respiratory allergic diseases.

BACKGROUND: Tenofovir disoproxil fumarate (DF) is a nucleotide analogue and a potent inhibitor of human immunodeficiency virus type 1 reverse transcriptase and hepatitis B virus (HBV) polymerase. METHODS: In two double-blind, phase 3 studies, we randomly assigned patients with hepatitis B e antigen (HBeAg)-negative or HBeAg-positive chronic HBV infection to receive tenofovir DF or adefovir dipivoxil (ratio, 2:1) once daily for 48 weeks. The primary efficacy end point was a plasma HBV DNA level of less than 400 copies per milliliter (69 IU per milliliter) and histologic improvement (i.e., a reduction in the Knodell necroinflammation score of 2 or more points without worsening fibrosis) at week 48. Secondary end points included viral suppression (i.e., an HBV DNA level of <400 copies per milliliter), histologic improvement, serologic response, normalization of alanine aminotransferase levels, and development of resistance mutations. RESULTS: At week 48, in both studies, a significantly higher proportion of patients receiving tenofovir DF than of those receiving adefovir dipivoxil had reached the primary end point (P<0.001). Viral suppression occurred in more HBeAg-negative patients receiving tenofovir DF than patients receiving adefovir dipivoxil (93% vs. 63%, P<0.001) and in more HBeAg-positive patients receiving tenofovir DF than patients receiving adefovir dipivoxil (76% vs. 13%, P<0.001). Significantly more HBeAg-positive patients treated with tenofovir DF than those treated with adefovir dipivoxil had normalized alanine aminotransferase levels (68% vs. 54%, P=0.03) and loss of hepatitis B surface antigen (3% vs. 0%, P=0.02). At week 48, amino acid substitutions within HBV DNA polymerase associated with phenotypic resistance to tenofovir DF or other drugs to treat HBV infection had not developed in any of the patients. Tenofovir DF produced a similar HBV DNA response in patients who had previously received lamivudine and in those who had not. The safety profile was similar for the two treatments in both studies. CONCLUSIONS: Among patients with chronic HBV infection, tenofovir DF at a daily dose of 300 mg had superior antiviral efficacy with a similar safety profile as compared with adefovir dipivoxil at a daily dose of 10 mg through week 48. (ClinicalTrials.gov numbers, NCT00116805 and NCT00117676.)

Ulcerative colitis [UC] is a chronic inflammatory bowel disease [IBD] characterised by colonic inflammation extending to a variable extent from the rectum. Care of the patient with UC requires appropriate input from across the multiprofessional team. These guidelines summarise the recommended medical treatment for adults with UC. Other ECCO guidelines consider the approach to UC diagnosis and monitoring,1–3 nursing care,4 management of disease complications,5–7 risk of infection,8 and technical aspects of surgery.9 This document was prepared as part of a process that also led to the publication of a related guideline with recommendations on the surgical care of the patients with UC and on the medical aspects of the management of the patient hospitalised with severe UC. ECCO Guidelines on Therapeutics in Ulcerative Colitis: Surgical Treatment. Patients living with UC can have a variable disease course.10 In this document, we discuss therapeutic approaches stratified by disease severity [mildly-to-moderately active and moderately-to-severely active disease]. Attempts to define disease severity are widely used in setting clinical trial inclusion criteria and can be measured according to several different definitions.11 Trial populations will inevitably vary, and we reflect the continuum of disease severity by having the moderate disease category span both broad categories. It is also important to remember that these definitions capture severity at a given point in time and may not reflect the cumulative long-term burden of disease experienced by a patient.12 It is also important to consider disease extent when planning treatment in UC, as this may affect the optimal route of drug administration. This is typically defined according to disease involving the rectum only [proctitis], disease distal to the splenic flexure [left-sided UC], or disease extending proximal to the splenic flexure [extensive UC].13 These definitions of disease extent are recognised as somewhat arbitrary; in clinical practice, topically administered therapies are often used for UC whose extent is limited to the rectum and a portion of the sigmoid colon [proctosigmoiditis], with the term ‘distal colitis’ used to describe this disease distribution. It should be remembered that disease distribution can change10,14 and that proximal disease extension can be a negative prognostic marker.15 This document was compiled following the ‘Grading of Recommendations Assessment, Development, and Evaluation’ [GRADE] methodology.16 A panel of 33 experts was selected by the Guidelines Committee of ECCO from a competitive pool of applicants and worked with a team of methodologists and librarians. All panellists received training in the GRADE methodology. Additionally, six patients with UC, representing the European Federation of Crohn’s and Colitis Associations [EFCCA], were invited to participate in all face-to-face meetings as full voting members. Two domains for the medical treatment of UC were identified and used as the basis for the following two working groups based upon disease severity: mildly-to-moderately active disease and moderately-to-severely active disease. We recognise that these divisions are somewhat arbitrary, partially overlapping, and inconsistently defined; therefore, we ensured close collaboration between the working groups to ensure that key topics were covered appropriately with the aim of providing guidance applicable across the continuum of UC severity encountered in clinical practice. Working group participants first formulated a series of specific questions using the Population, Intervention, Comparator, Outcomes [PICO] system, which were deemed to be clinically important for the medical treatment of UC. These questions were debated in a series of telephone conferences before final agreement at a meeting of the full guideline group in Vienna in November 2019. Voting on the inclusion of PICO questions was conducted, and only those achieving agreement of >80% by the panel were included in the next phase of the process. At this meeting, the panellists also ranked each outcome’s importance on a scale of 1 to 9 based on the GRADE definitions.16 Scores of 7‒9 indicated an outcome that is critical to patients for decision making; scores of 4‒6 indicated an important outcome, but not critical; and scores of 1‒3 indicated an outcome of limited importance. The panellists’ agreement on outcomes’ importance was assessed using the Disagreement Index, as described in the RAND/UCLA appropriateness method.17 The team of librarians performed a comprehensive literature search on PubMed/Medline, Embase, and the Cochrane Central databases, using specific search strings for each PICO question [available as Supplementary data at ECCO-JCC online]. Two working group members [one assigned to the PICO question and another from the same group as second reviewer] independently screened titles and abstracts to exclude any irrelevant reports. Subsequently, the working group members assigned to each PICO question assessed the full text of the selected publications for relevance to the specific PICO. Note that were only selected the PICO as data on at of the of for the of the In this that of a drug of were not included for not at outcome defined as of critical importance. of the the guidelines in this document from in patients with UC. The methodologists performed the The risk was used to treatment with were in with the in group of a we used a that was to the of the the we prepared and the using and We used for All are all for a and we on the in the The was based on the and the risk in the The of was using the following and each PICO we the of for each outcome, and the of across a guideline the of the extent to which the in the is to a the of the for each outcome across all we with the from as and assessed the following that to the of risk of and publication of was assessed using the Cochrane was assessed with the Cochrane a and the was according to the a different but related or outcome from the of was based on the of of was by when the of was and by two when was was assessed using and the and only were at included in the The of was a of the of across all critical for decision making; the of for any of the critical the of all used in each key data and for each outcome of and each of the of are as Supplementary with of the of We of of each of the the risk with the risk with the the and any the data in the with of the of across The of each was as that the of an the or or as that the is also the of and of between and and All recommendations were to voting by the panel the ECCO for each with six from the European of and from a of ECCO members in ECCO guideline The final of all was panel members a final meeting in and to a final recommendations were at of the panellists with the and The of text and and were by the ECCO also the final of these These guidelines are to and in on the medical treatment of should not be used to a of should not be used for and should not be as the of any or All with the and publication of this guideline were by The of ECCO in the of panel members or the or of PICO A of of the key from ECCO UC guidelines is in the Supplementary These guidelines the for the of different medical therapies in the treatment of UC. were and in a by the which were typically from clinical and based upon of an the medical care of a patient with UC the between a given drug and patients encountered in the not the of a given clinical trial It is important that these guidelines are used first to the of the of any given which the with the in a treatment A key of is when to is in UC in Crohn’s disease on the importance of treatment At the same the of can to and as can to the of an is a in the GRADE process when the of as guidelines will be that this document can not is that appropriate and of patients for is critical to optimal The of treatment in UC is to of and is important to not only of clinical but also as this is with long-term The importance of these was in the decision by the panel to and clinical as of critical importance. The term widely used in the to as and from therapies and This is somewhat as the of and to therapies with the of and are as a part of UC the of this we to the term as in the of any widely also the of this specific definitions of have used in these are in the for of the we typically in a both for patients disease or in appropriate or can a in clinical practice, are trial data in this and are to several of this we have recommendations to the in a in clinical In to the and of medical for UC, and when to consider or treatment to the and burden to patients of drug is an important The limited on treatment and is the of this We at a of to in patients with mildly-to-moderately active UC of We performed a of with a of patients for a in achieving clinical the clinical in at was for with in of patients with of those The of on as in with patients was with was The in with patients for a of was in the The of was as to and publication and for as Supplementary data at ECCO-JCC online]. A Cochrane the of or across This not any in between different of of colonic distribution of different in were in any this patients with active UC to with appropriately are to upon to an The same Cochrane not for of across when with of the same of the a of of a of with in patients with active disease or in those with treatment with or UC a of data also of in the group in the In according to disease severity not any in between and in of a We at a of for the of in active distal colitis We identified that assessed a of for which we used for as Supplementary data at ECCO-JCC All of inflammation but in the proximal of disease extent a of from the to was a in clinical and clinical when with patients and In in that assessed 1 for as in distal was in patients with those with in between treatment and were the of was as is the clinical and related to administration. We the of with for of in patients with active UC of at extent a were that the of with as for of in patients with active UC as Supplementary data at ECCO-JCC In all of these the of with the of this the of is Two these two therapeutic for clinical in patients with disease of at The were in of of clinical and of clinical In the of in clinical was is to in clinical in active These included patients and treatment was All were in of patient criteria used to define disease and and was a of and a risk of as the of and were in of The of clinical between and treatment was was only trial on the of on of Patients of of those with of the was not The of for this outcome was of assessed of the outcome of which was an and in the It is to the of treatment only trial this with were patients in the treatment group and patients in the group experienced In to this was also a risk of the of the data for this outcome was assessed to be we that the for clinical and the and risk of the all a in of in patients for was We using for the of in patients with active distal colitis The of topically administered for the of in patients with and distal the of a treatment with may be by patients to the route of administration. have on this but included all of the that was identified we performed a of that with as Supplementary data at ECCO-JCC were to in of clinical clinical and not with The of patients included in each was and the of was This was to and identified for the outcome critical outcome, critical were to have we that the with in clinical practice, the between and was in between and the of as an for of in patients with active UC. We treatment with for of in patients with active distal UC of The of treatment with at a or or for of in patients with active distal UC in We performed a of these which included a of patients with at or or with at as Supplementary data at ECCO-JCC online]. were for the of clinical but were not in clinical In patients for was to be with or In the of not between or the of was as patients should be with a is to that and may be of This may be appropriate for patients to to It is also important to be of between in of and all of which may have in patient It is appropriate to a patient a trial of an are to an We the of for of in patients with active UC of The of treatment with using 9 for of in patients with active UC in as Supplementary data at ECCO-JCC online]. A of patients with were included and for were to in clinical and clinical and In two patients for was to be with in with In all the of and of any not between and and The of in a of for this critical to A of data from both phase a clinical and of for 9 for of these data that this was in patients with the between drug and was not in those with disease. data for the of as a This that the appropriate of may be in patients with mildly-to-moderately active disease are not to or are to 9 with in patients with mildly-to-moderately active UC a in the of clinical and and in the treatment We the of as for the of in patients with active UC of Two have on the of as with for of in patients with only patients in two were and assessed for clinical with given a of We performed a of these and not a between and for of clinical as Supplementary data at ECCO-JCC online]. data on clinical or were It should be that to the of of may be appropriate to in patients with active disease with is but only when given an We not any using or for the of to related of we the of in of across the We the of at a for of in UC patients of We identified two involving participants with of which to PICO We these in a as Supplementary data at ECCO-JCC online]. clinical was that was to for in patients with UC was the of but this not for with was with the of was to be to with data for we appropriate to a given the and of this may be the of this inconsistently in the literature and may reflect in We the of for the of in patients with distal UC We identified that assessed as in patients with distal UC or as Supplementary data at ECCO-JCC used between 1 and 1 administered as or a of to [one The of was as a to risk of and The same were identified in a Cochrane The of as in patients with distal UC or was in of clinical with the of data on the of in distal UC or are for patients the of was to These not data on A Cochrane in the of patients or in the of to with with the of is is based on the clinical of and of of with the of this It is important to consider patient for the of the route for both in to and a of the route of may for with patients in and and may or should be We with for the of in patients with UC or are to moderate of We identified on treatment with in patients with UC were or to as Supplementary data at ECCO-JCC In patients for 1 was to for the of clinical data on or clinical or were In to clinical different disease and definitions were with and are the clinical of we not the of for of is important that any with is an We not any of but to related we across the drug with the of This is in patients of should be in this the of for the of in of to any in of clinical We for of in patients with moderately-to-severely active UC of a limited the of for the of in moderately-to-severely active UC is in clinical practice. The limited is in part to the and limited at the time of the A included only two of used we performed a of these two and an of for the of clinical The of was as to a risk of and part the of patients included in each was as Supplementary data at ECCO-JCC online]. with treatment was in these two Other the of in both and also in both UC and Crohn’s to the for of which are a outcome for we that the with in clinical and the between and used limited the of another as or as an for of in patients with moderately-to-severely active UC. these is as the of A identified six that with and a of of but with of these used a We recommendations for in active and in moderately-to-severely active UC, to reflect the populations of the identified and the in these different It is important to that are data the of as and limited data on the of these to Additionally, is with to with the of with to we of in patients with UC. should be for any patient disease or of or to Additionally, of should be to a of and with a should be for any patient requires a of in a or a disease upon We treatment with and to in patients with UC have or to We identified that with in patients with moderately-to-severely active UC as Supplementary data at ECCO-JCC an to or of which were defined as or both in also to or of of for of clinical and clinical We data for which is related to but defined from the outcome of used in this guideline was to was in of when of treatment data for from were that are not Two that performed that is to for the of clinical and The first also that is to and for of clinical and and and for of and and patients with a of of are limited data to treatment of a phase trial that the clinical of with were in patients with different from A of identified that the of when used in UC. was not to In patients with a of to or of clinical and were not are limited data on the of in A key question is to an with an The of with is data not for in with in UC, a for this and have in patients with Crohn’s patients of to a first used as and with of is in of of a to of to the second The optimal time point for the of to be in Crohn’s of used in the UC disease severe or as at first and inflammatory have to patients may from treatment the of this approach have not in any We treatment with for the of in patients with moderately-to-severely active UC have or to of Two were identified that PICO These included patients with moderately-to-severely active UC with or of clinical of clinical and were Patients were to as Supplementary data at ECCO-JCC online]. We included these two in a was often in patients with the of for clinical was the same as for clinical the between patients with and those was not of in patients with were not different from those data from also this was also for and data were of at in the phase were for patients with for patients In at in a phase not between and patients The of was The of was for clinical to and The of was moderate for clinical to The for both was to in between the two The of for was moderate to the was as the with the of in both and We treatment with to in patients with UC have or to moderate of We performed a of data from two to PICO These included patients with UC an of or were to or or a were with or as Supplementary data at ECCO-JCC was for in of clinical clinical and the was to and of on were were the was also to data are from of which should be when upon of The of an route of and the of should also be A of on data for clinical and in both the of patients to and the with were in of between these This was in the of that not of a between and or for clinical and in patients to but a or for patients with We treatment with for the of in patients with moderately-to-severely active UC with or to moderate of A with for in patients with moderately-to-severely active UC as Supplementary data at ECCO-JCC Patients were to have not to or to or as or or or have disease. of patients treatment with an treatment with both an and The the of in of clinical clinical and At of the in from was in those in those in from also a in the treatment not between and and with was for patients with and not a between and or for clinical and in patients to but a of or for patients with We or for the of in patients with UC to with the same drug We performed a of data from of for the of in patients with moderately-to-severely active UC as Supplementary data at ECCO-JCC were for the of clinical clinical in of and clinical The risk of was not different between and was also for and data were the of these In UC patients have to an is to for or the of therapeutic drug to clinical have an between of and and clinical in UC. these were all and any or a of based for of to in patients with disease of of patients with of to have that of or drug to with patients not to and to patients to to These data that by drug may be to be clinically decision but this requires in a The same and the to and not to the of of drug to in patients are not of in participants with UC, to with to at or by therapeutic drug The therapeutic drug was not to and was was a of clinical to were to drug with given the of appropriate we were to a as Supplementary data at ECCO-JCC and we in this We for of in patients with UC to with We identified that included patients with or which on of clinical and clinical in patients with moderately-to-severely active UC to as Supplementary data at ECCO-JCC Patients in these were for We performed a of from these was in received with clinical was also in patients with The of for these was moderate to The of across involving patients was not different between and The of for this outcome was moderate to from the of in a In the of in patients with UC in those with with for a both and of in patients with moderately-to-severely active UC, to and clinical were with with The was not to and all were between these two at in all and were with the We the of for the and of in patients with moderately-to-severely active colitis of the and of with those of a in patients with moderately-to-severely active UC as Supplementary data at ECCO-JCC A of patients in the group in the group clinical clinical and was a in of for clinical in a of patients in the group in the group the of for clinical was as on data and the were of and at with and with It is important to that was not with of with for both We for in patients with UC to with moderate of We identified that in patients with or as patients to at a of or was to in clinical and in patients with UC an to the the was to of clinical and in were also The clinical was also to on were for in were to The was to an risk for was of the were of and and A of the of across inflammatory a risk of This was also in a of data from the in UC were and with a This risk to be and is with A in that the of with with this risk to be in patients or in those A of in patients with and with at risk a risk of in patients with with patients with This risk was not in patients with data are in patients with risk in the UC these the European recommended using at the and as treatment for patients with risk In this UC patients with for at and in for were to with the same or to clinical were and for the and in or were between the two were in the data that is also with an risk of and we the that the in patients with with the with and of recommendations for as a treatment in patients with UC, with the and to be for each We for the of in patients with UC to with moderate of A with for in UC in patients to The that treatment with at of when with in of clinical and of clinical at data were not for we used data for the related of and with was a in for those on the The of were also by the scores in patients the not in the treatment In to the also also for clinical clinical and with were but this not The between with and were in patients with a of These recommendations summarise the on the medical management of patients with UC. were identified the of the which should be by is or is and recommendations be ECCO as or It is important that these guidelines the of and to and the and of We recognise that on care are an important in recommendations can be for patients in The recommendations should be used to treatment and part of an treatment for patients with UC, which may also and ECCO will these guidelines by ECCO and and will any to ECCO Guidelines clinical the ECCO will as a to the guideline recommendations can be clinical and patient care The important not as to for both and negative of These treatment guidelines will be according to the Committee for the of guidelines on the ECCO will the GRADE approach and consider the from clinical in the The ECCO guidelines are at care only and are based on an process. treatment are a for the and should not be based on the of the ECCO ECCO or any of members any may not be for any in in the ECCO ECCO a of of The is based on a used by the Committee of The are not only at the ECCO and the of but are also to on the ECCO providing a comprehensive of of of the We the ECCO for and for the literature and for the on and on the

Pseudomonas aeruginosa is one of the leading nosocomial pathogens worldwide. Nosocomial infections caused by this organism are often hard to treat because of both the intrinsic resistance of the species (it has constitutive expression of AmpC beta-lactamase and efflux pumps, combined with a low permeability of the outer membrane), and its remarkable ability to acquire further resistance mechanisms to multiple groups of antimicrobial agents, including beta-lactams, aminoglycosides and fluoroquinolones. P. aeruginosa represents a phenomenon of bacterial resistance, since practically all known mechanisms of antimicrobial resistance can be seen in it: derepression of chromosomal AmpC cephalosporinase; production of plasmid or integron-mediated beta-lactamases from different molecular classes (carbenicillinases and extended-spectrum beta-lactamases belonging to class A, class D oxacillinases and class B carbapenem-hydrolysing enzymes); diminished outer membrane permeability (loss of OprD proteins); overexpression of active efflux systems with wide substrate profiles; synthesis of aminoglycoside-modifying enzymes (phosphoryltransferases, acetyltransferases and adenylyltransferases); and structural alterations of topoisomerases II and IV determining quinolone resistance. Worryingly, these mechanisms are often present simultaneously, thereby conferring multiresistant phenotypes. This review describes the known resistance mechanisms in P. aeruginosa to the most frequently administrated antipseudomonal antibiotics: beta-lactams, aminoglycosides and fluoroquinolones.

MOTIVATION: Allergenicity, like antigenicity and immunogenicity, is a property encoded linearly and non-linearly, and therefore the alignment-based approaches are not able to identify this property unambiguously. A novel alignment-free descriptor-based fingerprint approach is presented here and applied to identify allergens and non-allergens. The approach was implemented into a four step algorithm. Initially, the protein sequences are described by amino acid principal properties as hydrophobicity, size, relative abundance, helix and β-strand forming propensities. Then, the generated strings of different length are converted into vectors with equal length by auto- and cross-covariance (ACC). The vectors were transformed into binary fingerprints and compared in terms of Tanimoto coefficient. RESULTS: The approach was applied to a set of 2427 known allergens and 2427 non-allergens and identified correctly 88% of them with Matthews correlation coefficient of 0.759. The descriptor fingerprint approach presented here is universal. It could be applied for any classification problem in computational biology. The set of E-descriptors is able to capture the main structural and physicochemical properties of amino acids building the proteins. The ACC transformation overcomes the main problem in the alignment-based comparative studies arising from the different length of the aligned protein sequences. The conversion of protein ACC values into binary descriptor fingerprints allows similarity search and classification. AVAILABILITY AND IMPLEMENTATION: The algorithm described in the present study was implemented in a specially designed Web site, named AllergenFP (FP stands for FingerPrint). AllergenFP is written in Python, with GIU in HTML. It is freely accessible at http://ddg-pharmfac.net/Allergen FP. CONTACT: idoytchinova@pharmfac.net or ivanbangov@shu-bg.net.

Analyzing the type and frequency of patient-specific mutations that give rise to Duchenne muscular dystrophy (DMD) is an invaluable tool for diagnostics, basic scientific research, trial planning, and improved clinical care. Locus-specific databases allow for the collection, organization, storage, and analysis of genetic variants of disease. Here, we describe the development and analysis of the TREAT-NMD DMD Global database (http://umd.be/TREAT_DMD/). We analyzed genetic data for 7,149 DMD mutations held within the database. A total of 5,682 large mutations were observed (80% of total mutations), of which 4,894 (86%) were deletions (1 exon or larger) and 784 (14%) were duplications (1 exon or larger). There were 1,445 small mutations (smaller than 1 exon, 20% of all mutations), of which 358 (25%) were small deletions and 132 (9%) small insertions and 199 (14%) affected the splice sites. Point mutations totalled 756 (52% of small mutations) with 726 (50%) nonsense mutations and 30 (2%) missense mutations. Finally, 22 (0.3%) mid-intronic mutations were observed. In addition, mutations were identified within the database that would potentially benefit from novel genetic therapies for DMD including stop codon read-through therapies (10% of total mutations) and exon skipping therapy (80% of deletions and 55% of total mutations).

BACKGROUND: This paper is a summary of the proceedings of the International Association of Paediatric Dentistry Bangkok Conference on early childhood caries (ECC) held in 3-4 November 2018. AIM: The paper aims to convey a global perspective of ECC definitions, aetiology, risk factors, societal costs, management, educational curriculum, and policy. DESIGN: This global perspective on ECC is the compilation of the state of science, current concepts, and literature regarding ECC from worldwide experts on ECC. RESULTS: Early childhood caries is related to frequent sugar consumption in an environment of enamel adherent, acid-producing bacteria in a complex biofilm, as well as developmental defects of enamel. The seriousness, societal costs, and impact on quality of life of dental caries in pre-school children are enormous. Worldwide data show that ECC continues to be highly prevalent, yet infrequently treated. Approaches to reduce the prevalence include interventions that start in the first year of a child's life, evidence-based and risk-based management, and reimbursement systems that foster preventive care. CONCLUSIONS: This global perspective on ECC epidemiology, aetiology, risk assessment, global impact, and management is aimed to foster improved worldwide understanding and management of ECC.

The prevalence of allergic airway diseases such as asthma and rhinitis has increased dramatically to epidemic proportions worldwide. Besides air pollution from industry derived emissions and motor vehicles, the rising trend can only be explained by gross changes in the environments where we live. The world economy has been transformed over the last 25 years with developing countries being at the core of these changes. Around the planet, in both developed and developing countries, environments are undergoing profound changes. Many of these changes are considered to have negative effects on respiratory health and to enhance the frequency and severity of respiratory diseases such as asthma in the general population. Increased concentrations of greenhouse gases, and especially carbon dioxide (CO2), in the atmosphere have already warmed the planet substantially, causing more severe and prolonged heat waves, variability in temperature, increased air pollution, forest fires, droughts, and floods - all of which can put the respiratory health of the public at risk. These changes in climate and air quality have a measurable impact not only on the morbidity but also the mortality of patients with asthma and other respiratory diseases. The massive increase in emissions of air pollutants due to economic and industrial growth in the last century has made air quality an environmental problem of the first order in a large number of regions of the world. A body of evidence suggests that major changes to our world are occurring and involve the atmosphere and its associated climate. These changes, including global warming induced by human activity, have an impact on the biosphere, biodiversity, and the human environment. Mitigating this huge health impact and reversing the effects of these changes are major challenges. This statement of the World Allergy Organization (WAO) raises the importance of this health hazard and highlights the facts on climate-related health impacts, including: deaths and acute morbidity due to heat waves and extreme meteorological events; increased frequency of acute cardio-respiratory events due to higher concentrations of ground level ozone; changes in the frequency of respiratory diseases due to trans-boundary particle pollution; altered spatial and temporal distribution of allergens (pollens, molds, and mites); and some infectious disease vectors. According to this report, these impacts will not only affect those with current asthma but also increase the incidence and prevalence of allergic respiratory conditions and of asthma. The effects of climate change on respiratory allergy are still not well defined, and more studies addressing this topic are needed. Global warming is expected to affect the start, duration, and intensity of the pollen season on the one hand, and the rate of asthma exacerbations due to air pollution, respiratory infections, and/or cold air inhalation, and other conditions on the other hand.

Cancer is one of the major cases of death in the world. Current treatment of cancer is limited to surgery, radiotherapy, and the use of cytotoxic agents, despite their well known side effects and problems associated with the development of resistance. For most forms of disseminated cancer, however, no curative therapy is available, and the discovery and development of novel active chemotherapeutic agents is largely needed. Since the development of cisplatin, an inorganic platinum complex, numerous platinum and non-platinum metal complexes were synthesized and tested for anticancer activity. Very few match the clinical efficacy of cisplatin. Ruthenium complexes were prepared to ameliorate cisplatin activity, particularly on resistant tumours, or to reduce host toxicity at active doses. Since many years a lot of scientific groups have actively worked in the field of inorganic antitumor drugs and have developed a number of Ru(II) and Ru(III) complexes, which were shown to possess good antitumor and, above all, antimetastatic properties against animal models. Ruthenium complexes are presently an object of great attention in the field of medicinal chemistry, as antitumor agents with selective antimetastatic properties and low systemic toxicity. Ruthenium compounds appear to penetrate reasonably well the tumor cells and bind effectively to DNA. In this review, the achievements in the field of medicinal chemistry, DNA binding modes, and the development status of Ru(II) and Ru(III) complexes as anticancer agents are discussed. The aim of this review is therefore that of critically examining the past and the actual work on ruthenium compounds with emphasis on their proposed role in cancer therapy.

This is the second of a series of two articles reporting the European Crohn's and Colitis Organisation [ECCO] evidence-based consensus on the management of adult patients with ulcerative colitis [UC]. The first article is focused on medical management, and the present article addresses medical treatment of acute severe ulcerative colitis [ASUC] and surgical management of medically refractory UC patients, including preoperative optimisation, surgical strategies, and technical issues. The article provides advice for a variety of common clinical and surgical conditions. Together, the articles represent an update of the evidence-based recommendations of the ECCO for UC.